Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton’s tyrosine kinase inhibitor
Substantial heterogeneity observed in cancer screening programme organisation and performance
Findings from the KRYSTAL-1 study cohort excluding NSCLC and CRC
Findings from the QuANTUM-First study
It is intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement
Findings from a large retrospective cohort study
Evidence for efficacy is based on the results from the POLARIX study
Findings from the NRG/RTOG 0631 study
Safety and efficacy were evaluated in Study P0501
Final results of the ROAR study
Modifiable lifestyle and cardiovascular risk factors associated with reduced risk for late mortality should be part of future interventions
Findings from a final prespecified overall survival analysis from the Study 309/KEYNOTE-775
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
